MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	CUI B. CHEN L. ZHANG S. MRÁZ Marek FECTEAU J.F. YU J. GHIA E.M. ZHANG L. BAO L. RASSENTI LZ. MESSER K. CALIN GA. CROCE CM. KIPPS TJ.
Year of publication	2014
Type	Article in Periodical
Magazine / Source	Blood
MU Faculty or unit	Central European Institute of Technology
Citation
Web	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110661/
Doi	http://dx.doi.org/10.1182/blood-2014-03-559690
Field	Oncology and hematology
Keywords	B-cell receptor; miR-155; chronic lymphocytic leukemia
Description	High-level leukemia cell expression of micro-RNA 155 (miR-155) is associated with more aggressive disease in patients with chronic lymphocytic leukemia (CLL), including those cases with a low-level expression of -chain-associated protein of 70 kD. CLL with high-level miR-155 expressed lower levels of Src homology-2 domain-containing inositol 5-phosphatase 1 and were more responsive to B-cell receptor (BCR) ligation than CLL with low-level miR-155. Transfection with miR-155 enhanced responsiveness to BCR ligation, whereas transfection with a miR-155 inhibitor had the opposite effect. CLL in lymphoid tissue expressed higher levels of miR155HG than CLL in the blood of the same patient. Also, isolated CD5(bright)CXCR4(dim) cells, representing CLL that had been newly released from the microenvironment, expressed higher levels of miR-155 and were more responsive to BCR ligation than isolated CD5(dim)CXCR4(bright) cells of the same patient. Treatment of CLL or normal B cells with CD40-ligand or B-cell-activating factor upregulated miR-155 and enhanced sensitivity to BCR ligation, effects that could be blocked by inhibitors to miR-155. This study demonstrates that the sensitivity to BCR ligation can be enhanced by high-level expression of miR-155, which in turn can be induced by crosstalk within the tissue microenvironment, potentially contributing to its association with adverse clinical outcome in patients with CLL.